Anzeige
Mehr »
Login
Samstag, 25.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QCWL | ISIN: SE0013719077 | Ticker-Symbol: 2AI
Frankfurt
24.01.25
08:03 Uhr
1,960 Euro
-0,006
-0,31 %
1-Jahres-Chart
QLIRO AB Chart 1 Jahr
5-Tage-Chart
QLIRO AB 5-Tage-Chart
GlobeNewswire (Europe)
85 Leser
Artikel bewerten:
(0)

Qliro AB: Qliro AB publishes Interim Report for Q3 2024: Shift to growth - increased momentum +35% contracted annual volume growth

Finanznachrichten News

The third quarter 2024 (third quarter 2023)

  • Total payment volume increased by 6% to SEK 2,922 million (2,757)
  • Operating income increased by 2% to SEK 96.1 million (94.0)
  • Adjusted operating expenses were SEK -80.8 million (-76.2)
  • Operating expenses amounted to SEK -86.4 million (-78.5)
  • Credit losses as a proportion of total payment volume were 0.9% (0.8)
  • Adjusted operating profit amounted to SEK -12.0 million (-4.5)
  • Operating profit totaled SEK -17.6 million (-6.7)
  • Profit/loss for the period was SEK -7.1 million (0.7)
  • Earnings per share before and after dilution amounted to SEK -0.37 (0.04)

January - September 2024 (January - September 2023)

  • Total payment volume increased by 5% to SEK 8,689 million (8,292)
  • Operating income increased by 7% to SEK 296.6 million (276.0)
  • Adjusted operating expenses were SEK -232.7 million (-232.8)
  • Operating expenses amounted to SEK -238.3 million (-235.1)
  • Credit losses as a proportion of total payment volumes totaled 0.9% (0.7)
  • Adjusted operating profit amounted to SEK -11.6 million (-17.4)
  • Operating profit totaled SEK -17.2 million (-19.6)
  • Profit/loss for the period was SEK -0.3 million (2.6)
  • Earnings per share before and after dilution amounted to SEK -0.02 (0.14)

Extract from CEO Christoffer Rutgersson's statement:
"According to plan, we are now focusing on growth over short-term profitability to take advantage of the new opportunities that have arisen after a competitor has divested its checkout. At the time of publication of this report we have secured agreements corresponding to approximately 35% volume growth, which are expected to drive equivalent income growth in the medium term. We realized 19% growth in total payment volume as early as October this year. The launch in Norway exceeded expectations by over NOK 300 million in agreed volumes within three months, and in January we are opening a new sales office in Finland. Our momentum has accelerated through product launches such as Checkout 0.0, which sets a new standard for conversion and which has been well received by merchants. Our ambition is to become the market leader in the Nordics.''

Presentation of the Interim Report
Today, November 15, 2024, at 10:00 a.m. CEO Christoffer Rutgersson and Interim CFO Mikael Rahm will present the Interim Report for the period January - September 2024. The presentation will be held in English.

Join via webcast
If you wish to participate via webcast, please use the link below. Via the webcast you are able to ask written questions.

Link: https://ir.financialhearings.com/qliro-q3-report-2024

Join via conference call
If you wish to participate via conference call please register on the link below. After registration you will be provided phone numbers and a conference/user ID to access the conference. You can ask questions verbally via the conference call.

Link: https://conference.financialhearings.com/teleconference/?id=50048611

For further information, please contact:

Christoffer Rutgersson
E-mail: ir@qliro.com

About Qliro AB

Qliro is a leading fintech company offering safe and simple digital payment solutions, including a complete check-out to e-merchants. Qliro is a credit market company under supervision of the Swedish Financial Supervisory Authority and has its registered address in Stockholm. Qliro's shares are listed on Nasdaq Stockholm under the ticker "Qliro".

For more information, please visit https://www.qliro.com/en-se/investor-relations

Interested in news and financial information from Qliro? Subscribe here.

This information is information that Qliro AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-11-15 08:50 CET.

© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.